title: [The influence of ocular surface diseases in the management of glaucoma].
abstract: BACKGROUND
  The medical treatment of glaucoma is frequently used as a first-line treatment. Often effective, this treatment is administered over the long term. Chronic administration of eye drops is implicated in ocular surface disease. The objective of this study was to determine the prevalence of ocular surface diseases (OSDs) in patients treated for glaucoma or ocular hypertension (OHT) as well as their influence on therapeutic management.
  
  
  METHODS
  Eighty-eight patients followed at the Quinze-Vingts National Ophthalmology Hospital for glaucoma or OHT were evaluated. All patients had a complete ocular examination including an evaluation of the ocular surface. A questionnaire derived from the Ocular Surface Disease Index (OSDI) was used to assess ocular surface symptoms and the related impairment of quality of life. According to the clinical evaluation of the ocular surface, patients were classified into three groups (A, no OSD; B, moderate OSD; C, severe OSD. The patients for whom ocular surface disease had modified the therapeutic management of glaucoma were identified.
  
  
  RESULTS
  In this study, 72 patients (82 %) showed significant symptoms of OSDs (OSDI score>22). A moderate or severe OSD was observed in 67 patients (76 %). For 33 patients (38 %), the OSD influenced the choice of glaucoma or OHT treatment. Among these patients, six had glaucoma surgery, one had laser trabeculoplasty, and 26 required one or several changes in eyedrops.
  
  
  CONCLUSIONS
  This study confirmed the high prevalence of OSDs in patients treated for glaucoma or OHT. For numerous patients, these pathologies influenced not only their quality of life but also their therapeutic management.
authors: Service d'ophtalmologie 3, CHNO des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France.
authors: C
authors: C
authors: Van Went
authors: E
authors: E
authors: Brasnu
authors: P
authors: P
authors: Hamard
authors: C
authors: C
authors: Baudouin
authors: A
authors: A
authors: Labbé
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000633:toxicity*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000633:toxicity*; D003430:Cross-Sectional Studies; D004359:Drug Therapy, Combination; D005128:Eye Diseases / Q000139:chemically induced* / Q000453:epidemiology*; D005260:Female; D018463:Filtering Surgery; D005500:Follow-Up Studies; D005901:Glaucoma / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000453:epidemiology; D009883:Ophthalmic Solutions; D011310:Preservatives, Pharmaceutical / Q000633:toxicity; D011446:Prospective Studies; D011788:Quality of Life; D011795:Surveys and Questionnaires; D014130:Trabeculectomy
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011310:Preservatives, Pharmaceutical